



(11) **EP 1 682 178 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
01.09.2010 Bulletin 2010/35

(45) Date of publication and mention
of the grant of the patent:
07.07.2010 Bulletin 2010/27

(21) Application number: **04810421.0**

(22) Date of filing: **04.11.2004**

(51) Int Cl.:
A61K 39/395 ^(2006.01) **A61K 38/20** ^(2006.01)
A61P 35/02 ^(2006.01)

(86) International application number:
PCT/US2004/036958

(87) International publication number:
WO 2005/044294 (19.05.2005 Gazette 2005/20)

(54) **METHODS OF THERAPY FOR CANCERS EXPRESSING THE CD40 ANTIGEN**
VERFAHREN ZUR BEHANDLUNG VON KREBS MIT EXPRESSION DES CD40-ANTIGENS
PROCEDES DE THERAPIE POUR DES CANCERS EXPRIMANT L'ANTIGENE CD40

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR**

(30) Priority: **04.11.2003 US 517337 P**
26.11.2003 US 525579 P
27.04.2004 US 565710 P

(43) Date of publication of application:
26.07.2006 Bulletin 2006/30

(60) Divisional application:
10006780.0

(73) Proprietors:
• **Novartis Vaccines and Diagnostics, Inc.**
Emeryville, CA 94608 (US)
• **XOMA Technology Ltd.**
Hamilton HM11 (BM)

(72) Inventors:
• **LONG, Li**
Emeryville, CA 94662-8097 (US)
• **LUQMAN, Mohammad**
Emeryville, CA 94662-8097 (US)
• **YABANNAVAR, Asha**
Emeryville, CA 94662-8097 (US)
• **ZAROR, Isabel**
Emeryville, CA 94662-8097 (US)

• **HURST, Deborah**
Emeryville, CA 94662-8097 (US)
• **LOPES DE MENEZES, Daniel, E.**
Emeryville, CA 94662-8097 (US)

(74) Representative: **Marshall, Cameron John et al**
Carpmaels & Ransford
One Southampton Row
London
WC1B 5HA (GB)

(56) References cited:
WO-A-01/83755 WO-A-02/28480
WO-A-02/28904 WO-A-02/088186

• **GISSELBRECHT CHRISTIAN ET AL: "Interleukin-2 treatment in lymphoma: A phase II multicenter study" BLOOD, vol. 83, no. 8, 1994, pages 2081-2085, XP002327659 ISSN: 0006-4971 cited in the application**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 682 178 B8

- ROSENBERG SA ET AL: "A PROGRESS REPORT ON THE TREATMENT OF 157 PATIENTS WITH ADVANCES CANCER USING LYMPHOKINE-ACTIVATED KILLER CELLS AND INTERLEUKIN-2 OR HIGH-DOSE INTERLEUKIN-2 ALONE" NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 316, no. 15, 2 April 1987 (1987-04-02), pages 889-897, XP001118518 ISSN: 0028-4793 cited in the application
- LITTLE M. ET AL: 'Of mice and men: hybridoma and recombinant antibodies' REVIEW IMMUNOLOGY TODAY vol. 21, no. 8, August 2000, pages 364 - 370
- ELLMARK PETER ET AL: 'Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library' IMMUNOLOGY vol. 106, 2002, pages 456 - 463